“First of its kind” manufacturing campus to bring 500 jobs to Ireland
pharmafile | September 19, 2016 | News story | Manufacturing and Production, Sales and Marketing | GE Healthcare, Ireland, manufacturing
Biopharma firm GE Healthcare has made a major investment to create a ‘BioPark’ in Ringaskiddy, Ireland, set to generate 500 new jobs.
The new manufacturing campus, named KUBio, claims to be the “first of its kind” in Europe: it will host a number of new companies, will provide prefabricated, off-the-shelf bio-manufacturing facilities, owned and run by GE customers, and will serve as focal point for further investment in next-generation biopharmaceutical manufacturing in Ireland.
The project comprises four KUBio sites, each owned by a separate company and making up 400 of the expected 500 jobs. GE will employ the remaining 100 on-site.
“The choice of Ireland for this strategically important investment by GE is a significant win,” commented Martin Shanahan, CEO of IDA.“The biopharmaceutical manufacturing campus will greatly assist IDA Ireland win additional bio-manufacturing investments by acting as a catalyst to attract new innovator drug companies and to transition and grow existing operations.”
The project is due to begin within 12 months.
Matt Fellows
Related Content

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

Meribel Pharma Solutions launches to take pharma services to new heights
Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






